STOCK TITAN

Simulations Plus to Participate in the Credit Suisse Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

LANCASTER, Calif.--()--Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will be participating in the Credit Suisse 29th Annual Virtual Healthcare Conference on Tuesday, November 10, 2020. Mr. O’Connor’s presentation will begin at 3:30 p.m. ET and will be webcast live.

The Company’s slide presentation will be available on the Investors page of the Simulations Plus website following the presentation. For more information about the Credit Suisse Virtual Healthcare Conference, or to register to attend, please visit the conference website.

About Simulations Plus, Inc.

Simulations Plus, Inc. is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com.

Follow us on Twitter | LinkedIn | YouTube

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
661-723-7723
renee@simulations-plus.com

Hayden IR
Mr. Cameron Donahue
651-653-1854
slp@haydenir.com

Simulations Plus Inc.

NASDAQ:SLP

SLP Rankings

SLP Latest News

SLP Stock Data

Computer Systems Design Services
Professional, Scientific, and Technical Services
Link
Technology Services, Packaged Software, Professional, Scientific, and Technical Services, Computer Systems Design Services
US
Lancaster

About SLP

simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res